EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Programming immunity in situ: A new frontier of in vivo cell engineering

Juliane Mietz iD, Antonela Merlotti iD, Antonin de Fougerolles, Olivier Demaria iD, Eric Vivier iD

Science Immunology · 06.11.2026 · 11 (125)

DOI: 10.1126/sciimmunol.aed1027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Immunology, erschienen am 06.11.2026. Verfasst von Juliane Mietz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille Université, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Ce…. Hauptthemen laut MEDLINE: Cell Engineering, Cell- and Tissue-Based Therapy. Die Arbeit nennt 187 Literaturangaben. Gefördert von: H2020 European Research Council, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vivo cell engineering enables the direct programming of immune cells inside patients. Instead of isolating, modifying, and reinfusing cells, therapeutic instructions are delivered directly to selected immune cells through lipid nanoparticles or viral vectors. This approach could facilitate rapid and scalable deployment of varied immune cell therapies across disease contexts. Early clinical studies in oncology and autoimmunity demonstrate increasing technical and clinical feasibility. The next challenge lies in enhancing precision to ensure that vectors reach the target cell type and tissue, deliver the appropriate payload, and produce desired transient or durable activity. Progress in targeting ligands, vector design, biodistribution control, and genome editing is beginning to address these barriers. Ensuring safety against immunogenicity, inflammatory toxicity, off-target editing, and uncontrolled persistence remains a central priority. By mastering these constraints, in vivo engineering could turn endogenous immune cells into therapeutic agents generated directly in the body, expanding cell therapy to diseases refractory to current modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell EngineeringCell- and Tissue-Based TherapyHumansAnimals

Autor:innen und Institutionen

  • Aix Marseille Université, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie de Marseille-Luminy (CIML), Marseille, France.
  • UMR 1356 (UPSaclay, INSERM, Gustave Roussy)-Next-Generation Immuno-Oncology Research and Therapy in Pediatric and Adult Cancer (NEXTIO), Villejuif, France.
  • PRISM Institute-National PRecISion Medecine Institute in Oncology Gustave Roussy, Villejuif, France.
  • Etherna, Niel, Belgium.
  • InVimmune, Marseille, France.
  • Valerio Therapeutics, Paris, France.

ORCID-Profile: Juliane Mietz, Antonela Merlotti, Olivier Demaria, Eric Vivier

Förderung

  • H2020 European Research Council
  • Agence Nationale de la Recherche
  • Fondation pour la Recherche Médicale
  • Institut National Du Cancer
  • Fondation Gustave Roussy

Zitieren

APA

Mietz, J., Merlotti, A., de Fougerolles, A., Demaria, O., & Vivier, E. (2026). Programming immunity in situ: A new frontier of in vivo cell engineering. Science Immunology, 11(125). https://doi.org/10.1126/sciimmunol.aed1027

Vancouver

Mietz J, Merlotti A, de Fougerolles A, Demaria O, Vivier E. Programming immunity in situ: A new frontier of in vivo cell engineering. Science Immunology. 2026;11(125). doi:10.1126/sciimmunol.aed1027

BibTeX
@article{Mietz2026,
  author = {Mietz, Juliane and Merlotti, Antonela and de Fougerolles, Antonin and Demaria, Olivier and Vivier, Eric},
  title = {Programming immunity in situ: A new frontier of in vivo cell engineering},
  journal = {Science Immunology},
  year = {2026},
  volume = {11},
  number = {125},
  doi = {10.1126/sciimmunol.aed1027}
}
Kostenlos starten →